Glaukos (GKOS) Q3 2026 Earnings Call Transcript
Glaukos (GKOS) reported Q3 2026 net sales of $211M, up 58% YoY. The company raised its 2026 net sales guidance to $775M-$785M and introduced preliminary 2027 revenue guidance of $1B. Q3 highlights include $53M in Epioxa net sales, 88% non-GAAP gross margin, and $28.5M in non-GAAP net income. The company plans to invest in its pipeline and market development initiatives.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise suggest strong demand for its pipeline products, likely driving short‑term price appreciation.
Market read
First‑report earnings and guidance raise provide fresh material for traders; positive sentiment expected.
What to watch
Potential regulatory or reimbursement hurdles for Epioxa and iDose TR could temper growth.
Background
Glaukos (GKOS) is a publicly traded ophthalmology company focusing on glaucoma and corneal treatments.
Ticker impact
Glaukos reported record Q3 net sales of $211M and raised FY2026 net sales guidance to $775‑$785M.
upward pressure as investors price in higher revenue expectations
The company delivered 58% sales growth and increased guidance by $90M, a material improvement that typically lifts the share price.
Market effects
Positive outlook for ophthalmology and glaucoma treatment sector, may boost peers.
U.S. biotech market may see modest uplift from strong guidance.
Limited to niche eye‑care market, no broad macro impact.
Counterpoint
If guidance is overly optimistic, future execution risk could lead to disappointment.
Key entities
- companyGlaukos
US‑listed ophthalmology firm
- productEpioxa
FDA‑approved corneal cross‑linking therapy
